Xilonix Phase III European Registration Study For Treatment Of Colorectal Cancer
Sunday, August 3, 2014 - 11:40
in Health & Medicine
XBiotech has begun its European Phase III study using its novel cancer drug Xilonix™ for the treatment of colorectal cancer. Xilonix is an antiobody works to block a number of processes that tumors use to grow and spread, such as potentially inhibiting the formation of tumor blood supply and new metastasis. Blocking tumor-related inflammation may also inhibit or reverse wasting and other illness associated with the malignancy. The double-blinded placebo controlled study is evaluating the use of the monoclonal antibody therapy designed to block chronic inflammation associated with malignant tumor growth. The treatment is reportedly aimed at reversing disease symptoms associated with disease progression and survival. read more